At ASH 2016, MPN experts from around the nation came together to review current and developing therapies for MPNs. Dr. John Mascarenhas of Mount Sinai School of Medicine in New York City discussed the use of agents that are currently approved for other conditions as well as JAK inhibitors in development. Dr. Catriona Jamieson from UC San Diegos Moores Cancer Center explains the possibility of therapy tailored to each patient, while Dr. Stephen Oh from Washington University School of Medicine expands on telomerase inhibitors and anti-fibrotic medicines.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo